Genetic determination of dyslipidemia – What tell us the results of genome-wide association studies?

Česká verzia

Authors: Jaroslav Alois Hubáček
Authors place of work: Centrum experimentální medicíny IKEM, Praha
Published in the journal: Vnitř Lék 2016; 62(11): 868-876
Category: Reviews

Summary

Dyslipidemia (high levels of plasma triglycerides and total cholesterol/LDL-cholesterol and low HDL-cholesterol) is considered as one of the major factors in the development of atherosclerosis and subsequent myocardial infarction. The final value of lipid parameters results from joint action of genetic predispositions and lifestyle factors (primarily smoking status, physical activity and in lower extent also diet). It is estimated that genetic factors are responsible for 40–80 % of the variability of plasma lipid values. Currently are as predictors DL analyzed mainly single nucleotide polymorphisms (SNPs). A fundamental shift in knowledge of genetic determination DL bring genome-wide association studies (GWAs). These revealed several dozen major polymorphisms in a DNA sequence related to lipid levels. Rather surprisingly, these variants are usually not substitutions of the amino acids, or causing a premature stop codon, but substitutions outside the genes. GWAS also found a number of variants within the genes whose function in lipid metabolism was completely unknown (e.g. gene for sortilin). Polymorphisms in genes for APOE, SORT1, LDLR (affect levels of total cholesterol and LDL-cholesterol), CETP, APOA1, ABCA-1, GALNT-2 (influence HDL-cholesterol) and finally in genes for APOA5, LPL or TRIB1 (affect the levels of triglycerides) but explains max. 30 % of the variability of plasma lipids. It is supposed, that rare polymorphisms/mutations and genetic factors unrelated directly to alterations in the DNA sequence (DNA methylation, histone modifications, regulatory RNA molecules) are responsible for the remaining proportion of DL determination.

Key words:
gene – cholesterol – interaction – mutation – polymorphism – triglycerides

Zdroje

1. Vítek L. Je cholesterol „good“ nebo opravdu „bad and ugly“? Hyper Kardiovask Prevence 2015; 4(1): 64–65.

2. Soška V, Vaverková H, Vráblík M et al. Stanovisko výboru ČSAT k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2011. Vnitř Lék 2013; 59(2): 120–126.

3. Ledford H. Cholesterol limits lose their lustre. Nature 2013; 494(7438): 410–411. Dostupné z DOI: <http://dx.doi.org/10.1038/494410a>. Erratum in Nature 2013; 495(7440): 155.

4. Windler E, Zyriax BC. Cholesterol-lowering therapy: Old evidence, new guidelines – Which one to follow? A critical appraisal. Atheroscler Suppl 2015; 18: 176–179. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosissup.2015.02.027>.

5. Vrablík M. Jak hluboko má cholesterol klesnout? Hypert Kardiovask Prevence 2014; 3(2): 32–36.

6. Češka R. Ateroskleróza, lipidy a interní medicína. Vnitř Lék 2015; 61(11): 919.

7. Liu J, Zeng FF, Liu ZM et al. Effect of blood triglycerides on cardiovascular and all-cause mortality – a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis 2013; 12: 159. Dostupné z DOI: <http://dx.doi.org/10.1186/1476–511X-12–159>.

8. Pikhart H, Hubáček JA, Persey A et al. Association between fasting plasma triglycerides, all-cause and cardiovascular mortality in Czech population. Results from the HAPIEE study. Physiol Res 2015; 64(Suppl 3): S355-S361.

9. Hubáček JA. Vysoký cholesterol není spojen s vyšší celkovou úmrtností. Hyper Kardiovask Prevence 2015; 4(1): 58–62.

10. Bruthans J, Cífková R, Lánská V et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014; 21(7): 829–839. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487312469476>.

11. Roberts R. Genetic of premature myocardial infarction. Curr Atheroscler Rep 2008; 10(3): 186–193.

12. Foulkes AS. Applied statistical genetics. For population-based association studies. Use R. Springer Science+Business Media LLC: 2009. ISBN 978–0-387–89554–3_1. Dostupné z DOI: <http://dx.doi.org/10.1007/978–0-387–89554–3_1>

13. Hubáček JA, Poledne R. Apolipoprotein E a jeho role v lipidovém metabolismu, kardiovaskulárních onemocněních a Alzheimerově chorobě. Prakt Lék 1998; 78(4): 162–165.

14. Hubacek JA. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin Chem Lab Med 2005; 43(9): 897–902.

15. Pennacchio LA, Olivier M, Hubacek JA et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001; 294(5540): 169–173.

16. Pennacchio LA, Olivier M, Hubacek JA et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002; 11(24): 3031–3038.

17. Ramasamy I. Update on the molecular biology of dyslipidemias. Clin Chim Acta 2016; 454: 143–185. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2015.10.033>.

18. Vrablík M, Schwarzová L, Freiberger T et al. Familiární hypercholesterolemie: klinické nálezy, molekulární genetika a diferenciální diagnostika. Ather Rew 2016; 1(1): 21–29.

19. Češka R, Vrablík M, Altschmiedová T et al. Familiární hypercholesterolemie včera a dnes. Vlastní zkušenosti a nálezy u našeho souboru nemocných s familiární hypercholesterolemií. Vnitř Lék 2014; 60(11): 963–969.

20. Soška V, Vrablík M, Bláha V et al. PCSK9 inhibitory – nové možnosti v léčbě hypercholesterolemie: u koho budou indikovány? Stanovisko České společnosti pro aterosklerózu. Vnitř Lék 2016; 62(4): 329–333.

21. Pitha J. Dietní zvyklosti a kardiovaskulární onemocnění. Vnitř Lék 2015; 61(9): 767–768.

22. Bláha V, Bláha M, Lánská M et al. Postavení lipoproteinové aferézy v současnosti. Vnitř Lék 2015; 61(11): 958–964.

23. Bláha V, Bláha M, Lánská M et al. LDL-aferéza v léčbě familiárních hyperlipoproteinemií. Vnitř Lék 2014; 60(1): 970–976.

24. Tveten K, Strøm TB, Cameron J et al. Mutations in the SORT1 gene are unlikely to cause autosomal dominant hypercholesterolemia. Atherosclerosis 2012; 225(2): 370–375. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2012.10.026>.

25. Tichý L, Freiberger T, Zapletalová P et al. The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations. Atherosclerosis 2012; 223(2): 401–408. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2012.05.014>.

26. Talmud PJ, Shah S, Whittall R et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013; 381(9874): 1293–1301. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)62127–8>.

27. Rosenthal E, Blue A, Jarvik GP. Next-generation gene discovery for variants of large impact on lipid traits. Curr Opin Lipidol 2015; 26(2): 114–119. Dostupné z DOI: <http://dx.doi.org/10.1097/MOL.0000000000000156>.

28. Hubáček JA, Vrablík M. Genetika dyslipidemií – včera, dnes a zítra. Vnitř Lék 2007; 53(4): 371–376.

29. Uitterlinden AG. An introduction to Genome-wide association studies: GWAS for dummies. Semin Reprod Med 2016; 34(4): 196–204. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0036–1585406>.

30. Kooner JS, Chambers JC, Aguilar-Salinas CA et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet 2008; 40(2): 149–151. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.2007.61>.

31. Vrablik M, Ceska R, Adamkova V et al. MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe. Hum Genet 2008; 124(5): 553–555. Dostupné z DOI: <http://dx.doi.org/10.1007/s00439–008–0577–6>.

32. Nakayama K, Bayasgalan T, Yamanaka K et al. Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. J Med Genet 2009; 46(6): 370–374. Dostupné z DOI: <http://dx.doi.org/10.1136/jmg.2008.064063>. Erratum in J Med Genet 2009; 46(12): 861.

33. Swerdlow DI, Holmes MV, Harrison S et al. The genetic of coronary heart disease. Br Med Bull 2012; 102: 59–77. Dostupné z DOI: <http://dx.doi.org/10.1093/bmb/lds009>.

34. Sanna S, Li B, Mullas A et al. Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double explained heritability. PLoS Genet 2011; 7(7): e1002198. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pgen.1002198>.

35. Kathiresan S, Melander O, Guiducci C et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40(2): 189–197. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.75>.

36. Sandhu MS, Waterworth DM, Debenham SL et al. LDL-cholesterol concentrations: a genome-wide association study. Lancet 2008; 371(9611): 483–491. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60208–1>.

37. Willer CJ, Sanna S, Jackson AU et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40(2): 161–169. 40(2): 161–9. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.76>.

38. Kathiresan S, Willer CJ, Peloto GM et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009; 41(1): 56–65. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.291>.

39. Aulchenko YS, Ripatti S, Lindquist I et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41(1): 47–55. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.269>.

40. Teslowich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466(7307): 707–713. Dostupné z DOI: <http://dx.doi.org/10.1038/nature09270>.

41. Swerdlow DI, Hingorani AD, Humphries SE. Genetic risk factors and Mendelian randomization in cardiovascular disease. Curr Cardiol Rep 2015; 17(5): 33. Dostupné z DOI: <http://dx.doi.org/10.1007/s11886–015–0584-x>.

42. Haase CL, Tybjærg-Hansen A, Qayyum AA et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 2012; 97(2): E248-E256. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2011–1846>.

43. Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res 2010; 51(8): 2032–2057. Dostupné z DOI: <http://dx.doi.org/10.1194/jlr.R004739>.

44. Johansen CT, Hegele RA. The complex genetic basis of plasma triglycerides. Curr Atheroscler Rep 2012; 14(3): 227–234. Dostupné z DOI: <http://dx.doi.org/10.1007/s11883–012–0243–2>.

45. Hegele RA, Ginsberg HN, Chapman MJ et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2(8): 655–666. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(13)70191–8>.

46. Schwarzova L, Hubacek JA, Vrablik M. Genetic predisposition to human plasma triglyceride concentration. Physiol Res 2015; 64(Suppl 3): S341-S354.

47. Hubacek JA. Apolipoprotein A5 fifteen years anniversary. Lessons from genetic epidemiology. Gene 2016; 592(1): 193–199. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gene.2016.07.070>.

48. Sarwar N, Sandhu MS, Ricketts SL et al. [Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration]. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375(9726): 1634–1639. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)60545–4>. Erratum in: Lancet 2010; 376(9735): 90.

49. Futema M, Shah S, Cooper JA et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61(1): 231–238. Dostupné z DOI: <http://dx.doi.org/10.1373/clinchem.2014.231365>.

50. Talmud PJ, Drenos F, Shah S et al. Gene-centric association signals for lipid and apolipoproteins identified via the Human CVD Bead Chip. Am J Hum Genet 2009; 85(5): 628–642. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajhg.2009.10.014>.

51. Willer CJ, Mohlke KL. Finding genes and variants for lipid levels after genome-wide association analysis. Curr Opin Lipidol 2012; 23(2): 98–103. Dostupné z DOI: <http://dx.doi.org/10.1097/MOL.0b013e328350fad2>.

52. Willer CJ, Schmidt EM, Sengupta S et al. [Global Lipids Genetics Consortium]. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45(11): 1274–1283. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.2797>.

53. Neřoldová M, Stránecký V, Hodaňová K et al. Rare variants in known and novel candidate genes predisposing to statin-associated myopathy. Pharmacogenomics 2016; 17(13): 1405–1414. Dostupné z DOI: <http://dx.doi.org/10.2217/pgs-2016–0071>.

54. Garcia-Rios A, Perez-Martinez P, Delgado-Lista J et al. Nutrigenetics of the lipoprotein metabolism. Mol Nutr Food Res 2012; 56(1): 171–183. Dostupné z DOI: <http://dx.doi.org/10.1002/mnfr.201100513>.

55. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell 2013; 153(1): 56–69. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2013.03.004>.

56. Blackmoreová S, Dawkins R. Teorie memů: kultura a její evoluce. Portál: Praha 2001. ISBN 80–7178–394–3.

57. Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA 2008; 299(11): 1345–1350. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.299.11.1345>.

58. Yet I, Tsai PC, Castillo-Fernandez JE et al. Genetic and environmental impacts on DNA methylation levels in twins. Epigenomics 2016; 8(1): 105–117. Dostupné z DOI: <http://dx.doi.org//10.2217/epi.15.90>.

59. Sharma P, Kumar J, Garg G et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol 2008; 27(7): 357–365. Dostupné z DOI: <http://dx.doi.org/10.1089/dna.2007.0694>.

60. Zhang Y, Zeng C. Role of DNA methylation in cardiovascular diseases. Clin Exp Hypert 2016; 38(3): 261–267. Dostupné z DOI: <http://dx.doi.org/10.3109/10641963.2015.1107087>.

61. Muka T, Koromani F, Portilla E et al. The role of epigenetic modifications in cardiovascular disease: A systematic review. Int J Cardiol 2016; 212: 174–183. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2016.03.062>.

62. Chen H, Wang L, Jiang J. Transcriptome and miRNA network analysis of familial hypercholesterolemia. Int J Mol Med 2014; 33(3): 670–676. Dostupné z DOI: <http://dx.doi.org/10.3892/ijmm.2013.1610>.

63. Najafi-Shoushtari SH. MicroRNAs in cardiometabolic disease. Curr Atheroscler Rep 2011; 13(3): 202–207. Dostupné z DOI: <http://dx.doi.org/10.1007/s11883–011–0179-y>.

64. Kaikkonen MU, Lam MT, Glass CK. Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res 2011; 90(3): 430–440. Dostupné z DOI: <http://dx.doi.org/10.1093/cvr/cvr097>.

65. Novák J, Souček M. MikroRNA a vnitřní lékařství: od patofyziologie k novým diagnostickým a terapeutickým postupům. Vnitř Lék 2016; 62(6): 477–485.